A single immediate postoperative prophylactic intravesical instillation of Pirarubicin following transurethral resection of non-muscle invasive bladder cancer
Phase 1
- Conditions
- non-muscle invasive bladder cancer (pTa and low grade)
- Registration Number
- JPRN-UMIN000004378
- Lead Sponsor
- Kobe University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
(1) patients with duplex of active other malignant disease. (2) Patients with history or present disease of upper urinary tract utotherial carcinoma. (3) Patients with severe disfunction of renal, liver, hematopoietic or heart. (4) Patients with history of allergic reaction against doxorubicin or epirubicin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of recurrence-free survival
- Secondary Outcome Measures
Name Time Method Two-year recurrence free survival rate Safty